TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04429438

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2
Description: Patients who have relapsed and refractory B cell lymphoma (BCL) after conventional chemotherapy will be treated with multiple 4SCAR gene-engineered T cells
Study: NCT02437240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pilates-based CPT
Description: To emphasize the self-perception of breathing and body core control during in-patient cardiopulmonary physical therapy following cardiac surgery

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional CPT
Description: A traditional in-patient cardiopulmonary physical therapy following cardiac surgery including airway clearance, breathing exercises, chest mobility and reconditioning exercises and so on
Study: NCT01840865

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: brain stimulation
Description: oscillating direct current brain stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: no stimulation
Description: sham Stimulation
Study: NCT03665441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eryaspase
Description: L-asparaginase encapsulated in erythrocytes (red blood cells)

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine plus Abraxane
Description: gemcitabine, Abraxane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus Abraxane
Description: gemcitabine, Abraxane

Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan plus 5-FU plus leucovorin
Description: irinotecan, 5-FU, leucovorin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan plus 5-FU plus leucovorin
Description: irinotecan, 5-FU, leucovorin
Study: NCT02728843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone
Description: 600 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone
Description: 600 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone
Description: 600 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone
Description: 600 mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets that match the deferiprone tablets in appearance
Study: NCT04152018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06940434
Description: PF-06940434 is given intravenously (IV) every 2 or 4 weeks in a 28 day cycle or every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06940434
Description: PF-06940434 is given intravenously (IV) every 2 or 4 weeks in a 28 day cycle or every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated
Study: NCT00879957

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: heparin
Description: Heparin will be added to PICC infusions at a dose of 0.5 units heparin per milliliter of intravenous fluid/parenteral nutrition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No heparin
Description: In the no heparin group, the subjects will not receive heparin as an additive to their PICC infusions.
Study: NCT03670290

Intervention type: PROCEDURE
Intervention: Fascia iliaca compartment catheter
Description: Patient will evaluate and if VAS score \>3, catheter will be inserted and 30 ml bupivacaine 0.25% will be applied after admission. Dose will be repeated VAS\>3 or patient enounce pain.
Study: NCT01013376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MC-1101
Description: MC-1101 1.0%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle
Study: NCT04073654

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of dental implants (surgical procedure)
Description: The two study implants have to be placed in the same surgical session according to similar procedures. Implants will be placed in the planned anatomic sites by using a flapless or a miniflap approach. Implants sites will be prepared based on the bone density, and according to the manufacturers's instruction by using the 122 Taper kit (Osstem Implant).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement of dental implants (surgical procedure)
Description: The two study implants have to be placed in the same surgical session according to similar procedures. Implants will be placed in the planned anatomic sites by using a flapless or a miniflap approach. Implants sites will be prepared based on the bone density, and according to the manufacturers's instruction by using the 122 Taper kit (Osstem Implant).
Study: NCT02332798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm
Study: NCT02535117

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Surgery(LS)
Description: For LS, the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg. Three to 4 working ports sized between 5 mm and 12 mm were used . Intra-operative ultrasonography was performed routinely. Parenchymal transection was performed using a Cavitron ultrasonic surgical aspirator (CUSA, Valleylab, Boulder, CO, USA). Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. A 1.0-cm safety margin was planed to get during the liver resection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RFA
Description: RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
Study: NCT01195558

Intervention type: OTHER
Intervention: Data collection on blindness and sleep problems
Description: Data related to degree of vision impairment and sleep problems is collected through a phone or web survey
Study: NCT01980394

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Esophageal Stump Washout
Description: a washout of the closed esophageal stump with Ringer-solution (10 times 30ml) is performed by means of a transorally inserted 24F-Foley catheter. The first, fifth and tenth portion of the lavage fluid are collected and sent to cytological examination
Study: NCT04478539

Intervention type: DEVICE
Intervention: Extracorporeal blood purification using the oXiris® (AN69ST) hemofilter
Description: Admitted patients will receive at least 1 cycle of extracorporeal blood purification using the oXiris® (AN69ST) hemofilter (Baxter, IL, USA). The number of cycles of blood purification is determined based on multiple biochemical, immunological, coagulation parameters, radiological imaging and overall clinical condition.~The patient is connected to the Prismaflex® oXiris® system via a double lumen catheter placed in the femoral vein or vena subclavia.~Flow rates will be maintained as follow; effluent dose 35 mL/Kg/h, dialysate 14 - 16 mL/Kg/h, blood 150 mL/min, replacement 16 -18 mL/Kg/h; patient fluid removal is tailored to the individual's volume status, ≈ 100 - 250 mL/h.~The oXiris® extracorporeal and organ support modality will be chosen according to the patient's kidney function; continuous venovenous hemofiltration (CVVH), continuous venovenous hemodiafiltration (CVVHDF) or slow continuous ultrafiltration (SCUF).
Study: NCT04152018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06940434
Description: PF-06940434 is given intravenously (IV) every 2 or 4 weeks in a 28 day cycle or every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06940434
Description: PF-06940434 is given intravenously (IV) every 2 or 4 weeks in a 28 day cycle or every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06940434
Description: PF-06940434 is given intravenously (IV) every 2 or 4 weeks in a 28 day cycle or every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06801591
Description: PF-06801591 will be administered subcutaneously on Day 1 of each 28 day cycle or Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06801591
Description: PF-06801591 will be administered subcutaneously on Day 1 of each 28 day cycle or Day 1 of each 21 day cycle.
Study: NCT01393691

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT with parent involved play
Description: This is a CBT adaptation designed for preschool children, which includes multiple standard cognitive-behavioral techniques, namely psycho-education, problem solving via play, gradual exposure and reinforcement management.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Triadic expressive play therapy
Description: Based on expressive play therapy guidelines, children and their parents will express themes concerning bedtime routines and fears via play.
Study: NCT02611219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General Health Module-Baseline Adolescent-Self Report (13-18 years)
Description: * 38 question questionnaire~* Answers range from 1=all of the time to 5=none of the time
Study: NCT04152018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06801591
Description: PF-06801591 will be administered subcutaneously on Day 1 of each 28 day cycle or Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06801591
Description: PF-06801591 will be administered subcutaneously on Day 1 of each 28 day cycle or Day 1 of each 21 day cycle.
Study: NCT02611219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General Health Module-Follow Up Adolescent-Self Report (13-18 years)
Description: * 38 question questionnaire about child~* Answers range from 1=all of the time to 5=none of the time

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General Health Module-Baseline Parent Report-Adolescent (13-18 years)
Description: * 38 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1-all of the time to 5=none of the time

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General Health Module-Follow Up Parent Report-Adolescent (13-18 years)
Description: * 38 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1-all of the time to 5=none of the time

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General Health Module-Baseline Parent Report-School Age (5-12 years)
Description: * 34 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1-all of the time to 5=none of the time

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General Health Module-Follow Up Parent Report-School Age (5-12 years)
Description: * 34 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1-all of the time to 5=none of the time

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Demographic Data Form
Description: -16 questions about demographics such as household income, race, and gender

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Demographic Data Form
Description: -16 questions about demographics such as household income, race, and gender
Study: NCT02260856

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tantalum Beads & Injector
Description: To measure growth at physis, four tantalum beads will be implanted per physis at baseline and take radiostereometric analysis measurements at all follow up timepoints. Tantalum beads have been used to make detailed three dimensional radiographic measurements in orthopedic and other specialties
Study: NCT03670290

Intervention type: PROCEDURE
Intervention: epidural catheter
Description: Patient will evaluate and if VAS score \>3, catheter will be inserted and 10 ml bupivacaine 0.25% will be applied after admission. Dose will be repeated VAS\>3 or patient enounce pain.

Intervention type: PROCEDURE
Intervention: patient controlled analgesia
Description: Patient will evaluate and if VAS score \>3, patient controlled analgesia pump will be set 1mg morphine/15 min lockout.
Study: NCT02611219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCT Daily Activity Log
Description: * Uses Fitbit Flex~* Log that lists time in 15 minute increments and allows for checking when out of bed and describing the activity that occurred while out of bed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCT Daily Activity Log
Description: * Uses Fitbit Flex~* Log that lists time in 15 minute increments and allows for checking when out of bed and describing the activity that occurred while out of bed
Study: NCT03002571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-124 Lotion
Description: IDP-124 Lotion, twice-daily application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP-124 Vehicle Lotion
Description: IDP-124 Vehicle Lotion, twice-daily application
Study: NCT00566566

Intervention type: OTHER
Intervention: sample without DNA
Description: family history, anthropometric measurements and blood sampling
Study: NCT02260856

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tantalum Beads & Injector
Description: To measure growth at physis, four tantalum beads will be implanted per physis at baseline and take radiostereometric analysis measurements at all follow up timepoints. Tantalum beads have been used to make detailed three dimensional radiographic measurements in orthopedic and other specialties

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Drill Epiphysiodesis
Study: NCT00562237

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: S205 placebo
Description: 2 i.m. injections per subject (0.5 mL each)
Study: NCT02260856

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Screw Epiphysiodesis
Study: NCT02611219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Functional Independence Measure for Children
Description: * 18-item, 7-level ordinal scale instrument that measures a child's consistent performance in essential daily functional skills. Three main domains (selfcare, mobility, and cognition) are assessed by interviewing or by observing a child's performance of a task to criterion standards~* Categorized into 2 main functional streams: Dependent (ie, requires helper: scores 1-5) and Independent (ie, requires no helper: scores 6-7). Scores 1 (total assistance) and 2 (maximal assistance) belongs to the Complete Dependence category. Scores 3 (moderate assistance), 4 (minimal contact assistance), and 5 (supervision or set-up) belongs to the Modified Dependence category. Scores 6 (modified independence) and 7 (complete independence) belongs to the Independent category.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Muscle Testing
Description: -Isometric muscle strength is tested in specific positions, usually with the muscle at an optimal working length. Using a break test, the test giver overpowers the muscle being tested to determine the muscle grade.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3-Minute Step Test
Description: * Using an aerobic step, the participant walks up and down for a given amount of time with the heart rate being checked before and after~* Using the difference in heart rate and a shortness of breath scale, this test is able to give an estimate of aerobic tolerance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HSCT Module-Follow Up Adolescent-Self Report (13-18 years)
Description: * 7 question questionnaire about child~* Answers range from 1=all of the time to 5=none of the time
Study: NCT00562237

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S205 10ugHA
Description: 2 i.m. injections per subject (0.5 mL each)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S205 30ugHA
Description: 2 i.m. injections per subject (0.5 mL each)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S205 10ugHA+500ugAlOH
Description: 2 i.m. injections per subject (0.5 mL each)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S205 30ugHA+500ugAlOH
Description: 2 i.m. injections per subject (0.5 mL each)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S205 10ugHA+1250ugAlOH
Description: 2 i.m. injections per subject (0.5 mL each)
Study: NCT02611219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HSCT Module-Follow Child-Self Report (5-12 years)
Description: * 10 question questionnaire about child~* Answers range from 1=all of the time to 5=none of the time

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HSCT Module-Follow Up Parent Report-adolescent (13-18 years)
Description: * 7 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1=all of the time to 5=none of the time
Study: NCT00562237

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S205 30ugHA+1250ugAlOH
Description: 2 i.m. injections per subject (0.5 mL each)
Study: NCT02611219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HSCT Module-Follow Up Parent Report-School Age (5-12 years)
Description: * 7 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1=all of the time to 5=none of the time
Study: NCT00675493

Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
Study: NCT02749071

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Laparoscopic implantation surgery
Description: Laparoscopic surgery to implant the pulse generator and bipolar lead.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic implantation surgery
Description: Laparoscopic surgery to implant the pulse generator and bipolar lead.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoStim stimulation for first six months of study
Description: Lower esophageal stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: EndoStim stimulation from Month 6 thru end of study
Description: Lower esophageal stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoStim stimulation from Month 6 thru end of study
Description: Lower esophageal stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham EndoStim stimulation for first six months of study
Description: EndoStim device remains off (no stimulation delivered)
Study: NCT03140943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib, Thalidomide and Dexamethasone
Description: Carfilzomib will be given on days 1,2,8,9,15,16 in a 4-week (28 day) cycle during induction cycles 1-12, followed by days 1,2,15,16 in a 4-week cycle during maintenance cycles 13-18 (section 4.0) Dexamethasone, 40mg po will be given on days 1,8,15, 22 in a 4-week cycle during induction cycles 1-12, followed by days 1,15, in a 4-week cycle during maintenance cycles 13-18.~Thalidomide, 100mg po will be given daily during induction cycles 1-12 only.
Study: NCT00851747

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phosphatidylcholine Deoxycholate
Description: Group A will serve as a control and will receive only injections of saline as a placebo. Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side. Group C will receive only study drug injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phosphatidylcholine Deoxycholate
Description: Group A will serve as a control and will receive only injections of saline as a placebo. Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side. Group C will receive only study drug injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Group A will serve as a control and will receive only injections of saline as a placebo. Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side. Group C will receive only study drug injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Group A will serve as a control and will receive only injections of saline as a placebo. Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side. Group C will receive only study drug injections
Study: NCT04395443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medication reconciliation
Description: the emergency clinical pharmacists will start medication reconciliation with the admitted patients and a full diseases and preadmission medications history will be taken.A comparison between the accuracy and completeness of drug history lists already presented in the profile and drug history taken by the clinical pharmacists to detect the medication discrepancies
Study: NCT02560597

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation
Description: Stimulation over the epileptogenic focus using variable stimulation protocols as described in literature. This protocol may vary case by case, depending on patient characteristics and achieved effect from previous stimulation.~In absence of effect, rTMS is given on 5 consecutive days at most.
Study: NCT02454491

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: intraradial administration of heparin 5000 ui

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: intraradial administration of verapamil 5 mg
Study: NCT02215512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRx-001 + WBRT
Description: Subjects will receive a combination of RRx-001 and whole brain radiotherapy.
Study: NCT02560571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood test
Study: NCT02762357

Intervention type: DEVICE
Intervention: Novosyn® Quick
Description: Episiotomy closure
Study: NCT01753271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: thoracic mobilization & shoulder mobilization & exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: shoulder mobilization & exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: shoulder mobilization & exercise
Study: NCT00935571

Intervention type: DRUG
Intervention: propofol, remifentanil, sevoflurane
Description: Propofol: using target controlled infusion (TCI); 1-3ug/ml remifentanil: using TCI by 5-20 ng/ml sevoflurane: 2-3volume% (1-2 MAC)